Verastem, Inc.

VSTM ·Healthcare, Drug Manufacturers - General, United States
Financial Statements Income Statement
Annual Quarterly

Income Statement

Line Item FY2026 FY2025 FY2024 FY2023 FY2022 FY2021 FY2020 FY2019
Revenue $30.9M $10.0M $2.6M $2.1M $88.5M $17.5M
Cost of Revenue
Gross Profit
Gross Margin
Operating Expenses
Research & Development $114.6M $81.3M $61.4M $50.6M $39.3M $41.4M $45.8M
SG&A Expense $81.1M $43.6M $30.7M $25.0M $24.1M $62.8M $101.2M
Operating Income $-170.1M $-115.0M $-92.1M $-72.9M $-61.4M $-49.4M $-132.3M
Operating Margin -550.3% -1,149.6% -2,809.6% -2,991.2% -55.8% -758.1%
Interest Expense $1.1M $4.6M $4.1M $2.1M $10.0M $15.8M $20.6M
Pretax Income $-209.5M $-130.5M $-87.4M $-73.8M $-71.2M $-67.5M $-149.2M
Income Tax Expense $185.0K $0 $0 $194.0K $0
Net Income $-209.5M $-130.6M $-87.4M $-73.8M $-71.2M $-67.7M $-149.2M
Net Margin -677.6% -1,306.4% -2,843.3% -3,468.1% -76.5% -854.8%
EPS (Basic) $-3.02 $-3.66 $-3.96 $-4.57 $-4.90 $-0.44 $-1.00
EPS (Diluted) $-3.02 $-3.66 $-3.96 $-4.57 $-4.90 $-0.44 $-1.00
Shares Outstanding (Basic) 87.8M 69.3M 35.7M 22.1M 16.1M 14.5M 153.3M 149.2M
Shares Outstanding (Diluted) 87.8M 69.3M 35.7M 22.1M 16.1M 14.5M 153.3M 149.2M
Dividends Per Share
← Newer Page 1 of 2 Older →